# EDGAR Filing Document

**Accession Number:** 0002007702
**File Stem:** 0001213900-25-070016
**Filing Date:** 2025-7
**Character Count:** 5559
**Document Hash:** 129cd76b55c7fe4b2fa7027f6c96cadb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-070016.hdr.sgml**: 20250731

**ACCESSION NUMBER**: 0001213900-25-070016

**CONFORMED SUBMISSION TYPE**: NT 20-F

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250331

**FILED AS OF DATE**: 20250731

**DATE AS OF CHANGE**: 20250731

**EFFECTIVENESS DATE**: 20250731

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Hong Kong Pharma Digital Technology Holdings Ltd
- **CENTRAL INDEX KEY:** 0002007702
- **STANDARD INDUSTRIAL CLASSIFICATION:** WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122]
- **ORGANIZATION NAME:** 07 Trade & Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** NT 20-F
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42468
- **FILM NUMBER:** 251172076

**BUSINESS ADDRESS:**
- **STREET 1:** ROOM B1, 5/F. WELL TOWN IND. BUILDING
- **STREET 2:** 13 KO FAI ROAD, YAU TONG
- **CITY:** KOWLOON
- **STATE:** K3
- **ZIP:** 00000
- **BUSINESS PHONE:** (852) 26189289

**MAIL ADDRESS:**
- **STREET 1:** ROOM B1, 5/F. WELL TOWN IND. BUILDING
- **STREET 2:** 13 KO FAI ROAD, YAU TONG
- **CITY:** KOWLOON
- **STATE:** K3
- **ZIP:** 00000

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 12b-25**

**SEC File Number <u>001-42468</u>**

**CUSIP Number <u>G6365B104</u>**

**NOTIFICATION OF LATE FILING**

(Check One): ☐ Form 10-K ☐ Form 11-K ☒ Form 20-F ☐ Form 10-Q <br> ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR

For Period Ended: <u>March 31, 2025</u>

☐ Transition Report on Form 10-K

☐ Transition Report on Form 20-F

☐ Transition Report on Form 11-K

☐ Transition Report on Form 10-Q

For Transition Period Ended:<u> </u>

**Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.**

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

**PART I – REGISTRANT INFORMATION**

**Hong Kong Pharma Digital Technology Holdings Limited**

Full Name of Registrant

**Room B1, 5/F., Well Town Industrial Building, 13 Ko Fai Road, Yau Tong, Kowloon**

Address of Principal Executive Office *(Street and Number)*

 

**Hong Kong, 00000**

City, State and Zip Code

**PART II – RULE 12-b 25 (b) AND (c)**

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate.)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The
 reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

☒ (b) The
 subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion
 thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report
 or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the
 fifth calendar day following the prescribed due date; and

(c) The
 accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

**PART III – NARRATIVE**

State below in reasonable detail the reasons why Form 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof could not be filed within the prescribed time period. (Attach extra sheets if needed.)

*The Registrant is unable to file its Annual Report on Form 20-F for the year ended March 31, 2025 (the "Form 20-F") because of unanticipated delays in the completion of its financial statements and related portions of the Form 20-F, which delays could not be eliminated by the Registrant without unreasonable effort and expense. In accordance with Rule 12b-25 under the Securities Exchange Act of 1934, as amended, the Registrant anticipates filing the Form 20-F no later than fifteen calendar days following the prescribed due date.*

**PART IV – OTHER INFORMATION**

&nbsp;&nbsp;&nbsp;&nbsp;(1) Name
 and telephone number of person to contact in regard to this notification

<u>Lap Sun Wong</u> <u>(+852)</u> <u>2618-9289</u> <br> (Name) (Area Code) (Telephone Number)

&nbsp;&nbsp;&nbsp;&nbsp;(2) Have
 all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment
 Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s)
 been filed? If the answer is no, identify report(s).

☒ Yes ☐ No

&nbsp;&nbsp;&nbsp;&nbsp;(3) Is
 it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be
 reflected by the earnings statements to be included in the subject report or portion thereof?

☐ Yes ☒ No

If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

**<u>HONG KONG PHARMA DIGITAL TECHNOLOGY HOLDINGS LIMITED</u>**

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: <u>July 31, 2025</u> | By: | /s/ Lap Sun Wong |
|  |  | Lap Sun Wong |
|  |  | Chief Executive Officer and Chairman |

---